Perceptions of drug costs may affect how much patients benefit from the drug, according to a study treating participants with a placebo. The results were published in the online issue of Neurology.
Perceptions of drug costs may affect how much patients benefit from the drug, according to a study treating participants with a placebo. The results were published in the online issue of Neurology.
In the study “Placebo effect of medication cost in Parkinson disease: A randomized double-blind study” from Alberto J. Espay, MD, MSc, of the University of Cincinnati in Ohio and a fellow of the American Academy of Neurology, and colleagues studied 12 patients with moderate to severe Parkinson disease and motor fluctuations. The patients were randomized to a “cheap” or “expensive” placebo. After 4 hours, they were crossed over the alternate arm.
"Patients' expectations play an important role in the effectiveness of their treatments, and the placebo effect has been well documented, especially in people with Parkinson's disease," Dr Espay said in a statement. "We wanted to see if the people's perceptions of the cost of the drug they received would affect the placebo response."
The participants were told the shots they were receiving were 2 formulations of the same drug that were believed to be of similar effectiveness, but that one cost $100 per dose and the other cost $1500 per dose. They were told the purpose of the study was to prove the drugs were equally effective despite their different price tags.
Both placebos improved motor function, but the benefit was greater when patients were randomized first to the expensive placebo. While the effect of the expensive placebo was less than levodopa, the placebo did significantly improve motor function and decrease brain activation.
After the participants were told the true purpose of the study.
"Eight of the participants said they did have greater expectations of the ‘expensive’ drug and were amazed at the extent of the difference brought about by their expectations," Dr Espay said. "Interestingly, the other 4 participants said they had no expectation of greater benefits of the more expensive drug, and they also showed little overall changes."
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More